NDATOPICALCREAM
Approved
Jan 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
HALOG-E (halcinonide) by PharmaIN is corticosteroid hormone receptor agonists [moa]. First approved in 1980.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALOG-E (halcinonide) is a potent topical corticosteroid cream approved in 1980 for inflammatory and pruritic dermatological conditions. It works by agonizing corticosteroid hormone receptors to reduce inflammation, edema, and pruritus in affected skin. The product is a small-molecule topical agent indicated for steroid-responsive dermatoses.
LOE Approaching
This mature, off-patent topical faces moderate competitive pressure (30%) with declining market relevance, suggesting a smaller, maintenance-focused commercial team.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, career opportunities on HALOG-E are extremely limited. This product is best suited for professionals seeking stable, maintenance-phase work in a mature market with no growth trajectory.
Brand Manager (Dermatology)Market Access Specialist
Worked on HALOG-E at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.